darolutamide
FDA Approves Nubeqa for Metastatic Castration-Sensitive Prostate Cancer
The FDA has approved Nubeqa for metastatic castration-sensitive prostate cancer.
JUNE 6, 2025
Darolutamide Triplet Therapy Improves Survival In mHSPC
Adding the androgen receptor inhibitor darolutamide (Nubeqa, Bayer/Orion) to androgen deprivation therapy (ADT) and ...
APRIL 12, 2022
Load more